Answers are grounded in this paper and cite their sources.
Granulocyte colony-stimulating factor (G-CSF) is the most common agent used for mobilizing peripheral blood (PB) hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematopoietic cell transplantation (allo-HCT).However, G-CSF mobilization often requires multiple leukapheresis procedures (LPs) and injections.1,2 G-CSF is also associated with bone pain, rare but life-threatening splenic rupture, and vaso-occlusive complications in patients with sickle-cell disease.1,[3][4][5] CXCR4 and SDF-1/CXCL12 interactions are crucial for HSPC retention within the bone marrow niche.[6][7][8] Plerixafor (AMD3100), is a low-affinity (Ki: 652 nM), short-acting CXCR4 inhibitor (CXCR4i) previously shown to mobilize PB HSPCs for HCT. [9][10]0][11] In these studies, up to 34% of allogeneic donors (allo-donors) mobilized with single-agent plerixafor failed to collect >2 × 10 6 CD34 + cells per kg with 1 injection and 1 LP; whereas 10% required ≥3 injections, ≥3 LPs, and G-CSF rescue.[11][12][13][14] Therefore, development of rapid and reliable HSPC mobilization regimens remains an unmet need.Motixafortide (BL-8040) is a novel 14-residue, cyclic, synthetic peptide CXCR4i with high affinity (Ki 0.32 nM) and slow receptor dissociation rate, previously shown to induce rapid (onset, 0.5-2 hours) and sustained (duration, >48 hours) HSPC mobilization.15 To our knowledge, the authors report the first trial evaluating motixafortide mobilization of allo-donors for HCT.
No takes yet. Share an insight, caveat, or question.
Crees et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: